<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ssmu</journal-id><journal-title-group><journal-title xml:lang="ru">Бюллетень сибирской медицины</journal-title><trans-title-group xml:lang="en"><trans-title>Bulletin of Siberian Medicine</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1682-0363</issn><issn pub-type="epub">1819-3684</issn><publisher><publisher-name>Siberian State Medical University, the Ministry of Healthcare of the Russian Federation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.20538/1682-0363-2024-2-162-182</article-id><article-id custom-type="elpub" pub-id-type="custom">ssmu-5674</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ И ЛЕКЦИИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEW AND LECTURES</subject></subj-group></article-categories><title-group><article-title>Прецизионная медицина в онкологии: роль и перспективы масс-спектрометрии</article-title><trans-title-group xml:lang="en"><trans-title>Precision medicine in oncology: role and prospects of mass spectrometry</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1776-4149</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Хмелевская</surname><given-names>Е. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Khmelevskaya</surname><given-names>E. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Хмелевская Екатерина Сергеевна – канд. мед. наук, науч. сотрудник, центр биологических исследований и биоинженерии, центральная научно-исследовательская лаборатория </p><p>634050, г. Томск, ул. Московский тракт, 2</p></bio><bio xml:lang="en"><p>2, Moscow Trakt, Tomsk, 634050</p></bio><email xlink:type="simple">kat.hmelevsk@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4273-8228</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Перина</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Perina</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Перина Екатерина Александровна – мл. науч. сотрудник, центр доклинических исследований, центральная научно-исследовательская лаборатория </p><p>634050, г. Томск, ул. Московский тракт, 2</p></bio><bio xml:lang="en"><p>2, Moscow Trakt, Tomsk, 634050</p></bio><email xlink:type="simple">catherineperina@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6714-1938</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Буйко</surname><given-names>Е. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Buyko</surname><given-names>E. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Буйко Евгений Евгеньевич – мл. науч. сотрудник, центральная научно-исследовательская лаборатория </p><p>634050, г. Томск, ул. Московский тракт, 2</p></bio><bio xml:lang="en"><p>2, Moscow Trakt, Tomsk, 634050</p></bio><email xlink:type="simple">buykoevgen@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3837-1179</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Уфандеев</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Ufandeev</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Уфандеев Александр Анатольевич – мл. науч. сотрудник, центр доклинических исследований, центральная научно-исследовательская лаборатория </p><p>634050, г. Томск, ул. Московский тракт, 2</p></bio><bio xml:lang="en"><p>2, Moscow Trakt, Tomsk, 634050</p></bio><email xlink:type="simple">ufandeev@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8761-7537</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кайдаш</surname><given-names>О. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kaidash</surname><given-names>O. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кайдаш Ольга Александровна – ст. науч. сотрудник, центр доклинических исследований, центральная научно-исследовательская лаборатория </p><p>634050, г. Томск, ул. Московский тракт, 2</p></bio><bio xml:lang="en"><p>2, Moscow Trakt, Tomsk, 634050</p></bio><email xlink:type="simple">kaidash_2011@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3326-729X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Иванов</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Ivanov</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Иванов Владимир Владимирович – канд. биол. наук, доцент, руководитель центра доклинических исследований, центральная научно-исследовательская лаборатория </p><p>634050, г. Томск, ул. Московский тракт, 2</p></bio><bio xml:lang="en"><p>2, Moscow Trakt, Tomsk, 634050</p></bio><email xlink:type="simple">ivanovvv1953@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0538-9361</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Байков</surname><given-names>А. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Baikov</surname><given-names>A. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Байков Александр Николаевич – д-р мед. наук, профессор, зам. проректора СибГМУ </p><p>634050, г. Томск, ул. Московский тракт, 2</p></bio><bio xml:lang="en"><p>2, Moscow Trakt, Tomsk, 634050</p></bio><email xlink:type="simple">baikov.an@ssmu.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8385-6052</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Парочкина</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Parochkina</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Парочкина Екатерина Владимировна – инженер-исследователь, лаборатория молекулярной медицинской диагностики </p><p>117303, г. Москва, ул. Керченская, 1А/1</p></bio><bio xml:lang="en"><p>1А/1, Kerchenskaya Str., Moscow, 117303</p></bio><email xlink:type="simple">shamarina.ev@phystech.edu</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6104-4782</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Удут</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Udut</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Удут Елена Владимировна – д-р мед. наук, профессор РАН, зав. центральной научно-исследовательской лабораторией </p><p>634050, г. Томск, ул. Московский тракт, 2</p></bio><bio xml:lang="en"><p>2, Moscow Trakt, Tomsk, 634050</p></bio><email xlink:type="simple">udut.ev@ssmu.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Сибирский государственный медицинский университет (СибГМУ)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Siberian State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Московский физико-технический институт (национальный исследовательский университет)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Moscow Institute of Physics and Technology (National Research University)</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>11</day><month>07</month><year>2024</year></pub-date><volume>23</volume><issue>2</issue><fpage>162</fpage><lpage>182</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Хмелевская Е.С., Перина Е.А., Буйко Е.Е., Уфандеев А.А., Кайдаш О.А., Иванов В.В., Байков А.Н., Парочкина Е.В., Удут Е.В., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Хмелевская Е.С., Перина Е.А., Буйко Е.Е., Уфандеев А.А., Кайдаш О.А., Иванов В.В., Байков А.Н., Парочкина Е.В., Удут Е.В.</copyright-holder><copyright-holder xml:lang="en">Khmelevskaya E.S., Perina E.A., Buyko E.E., Ufandeev A.A., Kaidash O.A., Ivanov V.V., Baikov A.N., Parochkina E.V., Udut E.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://bulletin.ssmu.ru/jour/article/view/5674">https://bulletin.ssmu.ru/jour/article/view/5674</self-uri><abstract><p>Цель исследования – анализ накопленных данных о применении методов масс-спектрометрии в диагностике, лечении и прогнозировании течения онкологических заболеваний с позиций прецизионной медицины. На сегодняшний день не существует общепризнанных методов ранней диагностики рака, так как патологические изменения на начальных стадиях развития обладают низкой молекулярной специфичностью, а существующие методы известны своей ограниченной чувствительностью. Однако именно возможность как можно более ранней диагностики является важным, если не определяющим, фактором адекватного выбора стратегии терапии онкологических заболеваний и ее успешного применения. В этом контексте высокотехнологические подходы к профилированию молекулярного ландшафта тканей, использующие в своей основе метод масс-спектрометрии, имеют большой потенциал к развитию и применению в области онкологии. Современная масс-спектрометрия становится незаменимым инструментом в проведении фундаментальных и прикладных исследований за счет своей чувствительности, специфичности и точности, обеспечивающим эффективный анализ сложных биологических соединений даже в незначительных концентрациях. Важным свойством современных масс-спектрометрических технологий является возможность автоматизации аналитического процесса, что открывает перспективы широкого внедрения в клиническую практику на этапах постановки диагноза, выбора стратегии лекарственной терапии и даже сопровождения работы хирурга-онколога в операционной. С учетом всех приведенных выше характеристик и преимуществ масс-спектрометрические методы анализа биологических образцов можно определить как один из наиболее перспективных и динамически развивающихся инструментов прецизионной медицины вследствие их способности на базе омиксных технологий предоставить клинически ценную информацию с учетом персональных особенностей пациента. В ближайшее десятилетие можно ожидать, что внедрение методов, основанных на технологии масс-спектрометрии, в клиническую практику, стоящую на принципах прецизионной медицины, приведет к оптимизации процесса определения индивидуальных стратегий лечения онкологических больных и принесет значительный экономический эффект за счет снижения заболеваемости, инвалидности и смертности. В настоящей обзорной статье представлен анализ 65 научных публикаций, посвященных результатам клинических и экспериментальных исследований, в которых методы масс-спектрометрического анализа применялись для диагностики онкологических заболеваний, выяснения механизмов их развития и оценки эффективности терапевтических воздействий. Обзор включает оригинальные статьи, опубликованные в период с 1 января 2018 г. по 30 ноября 2023 г. Большинство исследований подтверждают, что масс-спектрометрия является перспективным инструментом в онкологической диагностике и мониторинге эффективности лечения. Расширение использования методов масс-спектрометрии в онкологии имеет большой потенциал и является актуальной задачей для дальнейших исследований.</p></abstract><trans-abstract xml:lang="en"><p>The aim of this review was to analyze the accumulated data on the use of mass spectrometry in diagnosing, treating, and prognosing cancer from the perspective of precision medicine. Currently, universally accepted methods for early cancer diagnosis are not available, primarily due to low molecular specificity of pathological changes at early stages of cancer development. Additionally, the existing diagnostic modalities are notably limited in sensitivity. However, early detection is imperative for selection of the most suitable cancer treatment strategy and its successful implementation. In the realm of oncology, mass spectrometry approaches show great potential for advancement and utilization. Mass spectrometry is becoming an indispensable tool in basic and applied research due to its sensitivity, specificity, and accuracy. It allows for efficient analysis of complex biological compounds, even at low concentrations. Moreover, contemporary mass spectrometry technology is capable of automating the analysis, thereby facilitating its diverse clinical applications in diagnosis, drug therapy selection, and even potential assistance to surgical oncologists in the operating room. Considering all these characteristics and advantages, mass spectrometry methods for the analysis of biological samples can be defined as some of the most promising and dynamically developing tools in precision medicine, as they are capable of providing clinically valuable information based on omics technologies, taking into account personal characteristics of the patient. Over the next decade, introduction of mass spectrometry-based methods into clinical practice based on the principles of precision medicine is expected to optimize selection of personalized treatment strategies for cancer patients and provide significant economic benefits by reducing morbidity, disability, and mortality.This comprehensive review presents the analysis of 65 scientific publications, highlighting the results of clinical and experimental studies utilizing mass spectrometry methods for diagnosing cancer, investigating the underlying mechanisms of disease development, and evaluating the efficacy of therapeutic interventions. The review encompasses original articles published from January 1, 2018 to November 30, 2023. The majority of studies back the potential of mass spectrometry as a valuable tool for cancer diagnosis and treatment monitoring. Broadening application of mass spectrometry techniques in the field of oncology holds significant promise and represents a relevant area for future research.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>масс-спектрометрическое исследование</kwd><kwd>масс-спектрометрия</kwd><kwd>молекулярное профилирование</kwd><kwd>рак</kwd><kwd>опухолевой процесс</kwd><kwd>канцерогенез</kwd><kwd>низкомолекулярные метаболиты</kwd></kwd-group><kwd-group xml:lang="en"><kwd>mass spectrometric study</kwd><kwd>mass spectrometry</kwd><kwd>molecular profiling</kwd><kwd>cancer</kwd><kwd>tumor process</kwd><kwd>carcinogenesis</kwd><kwd>low-molecular-weight metabolites</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Исследование выполнено при финансовой поддержке РНФ в рамках научного проекта «Новые подходы валидации результатов молекулярного профилирования патологических изменений тканей на основе данных молекулярного профилирования, полученных при исследовании биопсии и аутопсии» № 23-69-10035.</funding-statement><funding-statement xml:lang="en">The study was supported by the Russian Science Foundation as part of the research project No. 23-69-10035 “New approaches to validating the results of molecular profiling of tissue pathological changes based on molecular profiling data obtained during biopsy and autopsy studies”.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">https://www.who.int/ru/news-room/fact-sheets/detail/cancer</mixed-citation><mixed-citation xml:lang="en">https://www.who.int/ru/news-room/fact-sheets/detail/cancer</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">https://www.who.int/ru/health-topics/cancer#tab=tab_1</mixed-citation><mixed-citation xml:lang="en">https://www.who.int/ru/health-topics/cancer#tab=tab_1</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Al-Zhoughbi W., Huang, J., Paramasivan G.S., Till H., Pichler M., Guertl-Lackner B. et al. Tumor macroenvironment and metabolism. Seminars in Oncology. 2014;41(2):281–295. DOI: 10.1053/j.seminoncol.2014.02.005</mixed-citation><mixed-citation xml:lang="en">Al-Zhoughbi W., Huang, J., Paramasivan G.S., Till H., Pichler M., Guertl-Lackner B. et al. Tumor macroenvironment and metabolism. Seminars in Oncology. 2014;41(2):281–295. DOI: 10.1053/j.seminoncol.2014.02.005</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Beatty A., Fink L.S., Singh T., Strigun A., Peter E., Ferrer C.M. et al. Metabolite profiling reveals the glutathione biosynthetic pathway as a therapeutic target in triple-negative breast cancer. Molecular Cancer Therapeutics. 2018;17(1):264–275. DOI: 10.1158/1535-7163.MCT-17-0407.</mixed-citation><mixed-citation xml:lang="en">Beatty A., Fink L.S., Singh T., Strigun A., Peter E., Ferrer C.M. et al. Metabolite profiling reveals the glutathione biosynthetic pathway as a therapeutic target in triple-negative breast cancer. Molecular Cancer Therapeutics. 2018;17(1):264–275. DOI: 10.1158/1535-7163.MCT-17-0407.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Mayerle J., Kalthoff H., Reszka R., Kamlage B., Peter E., Schniewind B. et al. Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis. Gut. 2018;67(1):128–137. DOI: 10.1136/gutjnl-2016-312432.</mixed-citation><mixed-citation xml:lang="en">Mayerle J., Kalthoff H., Reszka R., Kamlage B., Peter E., Schniewind B. et al. Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis. Gut. 2018;67(1):128–137. DOI: 10.1136/gutjnl-2016-312432.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Wojakowska A., Cole L.M., Chekan M., Bednarczyk K., Maksymiak M., Oczko-Wojciechowska M. et al. Discrimination of papillary thyroid cancer from non-cancerous thyroid tissue based on lipid profiling by mass spectrometry imaging. Endokrynologia Polska. 2018;69(1): 2–8. DOI: 10.5603/EP.a2018.0003.</mixed-citation><mixed-citation xml:lang="en">Wojakowska A., Cole L.M., Chekan M., Bednarczyk K., Maksymiak M., Oczko-Wojciechowska M. et al. Discrimination of papillary thyroid cancer from non-cancerous thyroid tissue based on lipid profiling by mass spectrometry imaging. Endokrynologia Polska. 2018;69(1): 2–8. DOI: 10.5603/EP.a2018.0003.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Yang W., Mu T., Jiang J., Sun Q., Hou X., Sun Y. et al. Identification of potential biomarkers and metabolic profiling of serum in ovarian cancer patients using UPLC/Q-TOF MS. Cellular Physiology and Biochemistry. 2018;51(3):1134–1148. DOI: 10.1159/000495492.</mixed-citation><mixed-citation xml:lang="en">Yang W., Mu T., Jiang J., Sun Q., Hou X., Sun Y. et al. Identification of potential biomarkers and metabolic profiling of serum in ovarian cancer patients using UPLC/Q-TOF MS. Cellular Physiology and Biochemistry. 2018;51(3):1134–1148. DOI: 10.1159/000495492.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Farshidfar F., Kopciuk K.A., Hilsden R., McGregor S.E., Mazurak V.C., MacLean A. et al. A quantitative multimodal metabolomic assay for colorectal cancer. BMC Сancer. 2018;18(1): 1–12. DOI: 10.1186/s12885-017-3923-z.</mixed-citation><mixed-citation xml:lang="en">Farshidfar F., Kopciuk K.A., Hilsden R., McGregor S.E., Mazurak V.C., MacLean A. et al. A quantitative multimodal metabolomic assay for colorectal cancer. BMC Сancer. 2018;18(1): 1–12. DOI: 10.1186/s12885-017-3923-z.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Bonaparte E., Pesenti C., Fontana L., Falcone R., Paganini L., Marzorati A. et al. Molecular profiling of lung cancer specimens and liquid biopsies using MALDI-TOF mass spectrometry. Diagnostic Pathology. 2018;13(1):1–9. DOI: 10.1186/s13000-017-0683-7.</mixed-citation><mixed-citation xml:lang="en">Bonaparte E., Pesenti C., Fontana L., Falcone R., Paganini L., Marzorati A. et al. Molecular profiling of lung cancer specimens and liquid biopsies using MALDI-TOF mass spectrometry. Diagnostic Pathology. 2018;13(1):1–9. DOI: 10.1186/s13000-017-0683-7.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Wippel H.H., Santos M.D. M., Clasen M.A., Kurt L.U., Nogueira F.C.S., Carvalho C.E. et al. Comparing intestinal versus diffuse gastric cancer using a PEFF-oriented proteomic pipeline. Journal of Proteomics. 2018;171:63–72. DOI: 10.1016/j.jprot.2017.10.005.</mixed-citation><mixed-citation xml:lang="en">Wippel H.H., Santos M.D. M., Clasen M.A., Kurt L.U., Nogueira F.C.S., Carvalho C.E. et al. Comparing intestinal versus diffuse gastric cancer using a PEFF-oriented proteomic pipeline. Journal of Proteomics. 2018;171:63–72. DOI: 10.1016/j.jprot.2017.10.005.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Phua L.C., Goh S., Tai D.W.M., Leow W.Q., Alkaff S.M.F., Chan C.Y. et al. Metabolomic prediction of treatment outcome in pancreatic ductal adenocarcinoma patients receiving gemcitabine. Cancer Chemotherapy and Pharmacology. 2018;81:277–289. DOI: 10.1007/s00280-017-3475-6.</mixed-citation><mixed-citation xml:lang="en">Phua L.C., Goh S., Tai D.W.M., Leow W.Q., Alkaff S.M.F., Chan C.Y. et al. Metabolomic prediction of treatment outcome in pancreatic ductal adenocarcinoma patients receiving gemcitabine. Cancer Chemotherapy and Pharmacology. 2018;81:277–289. DOI: 10.1007/s00280-017-3475-6.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Müller A.K., Föll M., Heckelmann, B., Kiefer S., Werner M., Schilling O. et al. Proteomic characterization of prostate cancer to distinguish nonmetastasizing and metastasizing primary tumors and lymph node metastases. Neoplasia. 2018;20(2):140–151. DOI: 10.1016/j.neo.2017.10.009.</mixed-citation><mixed-citation xml:lang="en">Müller A.K., Föll M., Heckelmann, B., Kiefer S., Werner M., Schilling O. et al. Proteomic characterization of prostate cancer to distinguish nonmetastasizing and metastasizing primary tumors and lymph node metastases. Neoplasia. 2018;20(2):140–151. DOI: 10.1016/j.neo.2017.10.009.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Lee J., Hua S., Lee S.H., Oh M.J., Yun J., Kim J.Y. et al. Designation of fingerprint glycopeptides for targeted glycoproteomic analysis of serum haptoglobin: insights into gastric cancer biomarker discovery. Analytical and Bioanalytical Chemistry. 2018;410:1617–1629. DOI: 10.1007/s00216-017-0811-y.</mixed-citation><mixed-citation xml:lang="en">Lee J., Hua S., Lee S.H., Oh M.J., Yun J., Kim J.Y. et al. Designation of fingerprint glycopeptides for targeted glycoproteomic analysis of serum haptoglobin: insights into gastric cancer biomarker discovery. Analytical and Bioanalytical Chemistry. 2018;410:1617–1629. DOI: 10.1007/s00216-017-0811-y.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Lončar-Brzak B., Klobučar M., Veliki-Dalić I., Sabol I., Kraljević Pavelić S., Krušlin B. et al. Expression of small leucine-rich extracellular matrix proteoglycans biglycan and lumican reveals oral lichen planus malignant potential. Clinical Oral Investigations. 2018;22:1071–1082. DOI: 10.1007/s00784-017-2190-3.</mixed-citation><mixed-citation xml:lang="en">Lončar-Brzak B., Klobučar M., Veliki-Dalić I., Sabol I., Kraljević Pavelić S., Krušlin B. et al. Expression of small leucine-rich extracellular matrix proteoglycans biglycan and lumican reveals oral lichen planus malignant potential. Clinical Oral Investigations. 2018;22:1071–1082. DOI: 10.1007/s00784-017-2190-3.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang Y., Ding N., Cao Y., Zhu Z., Gao P. Differential diagnosis between hepatocellular carcinoma and cirrhosis by serum amino acids and acylcarnitines. International Journal of Clinical and Experimental Pathology. 2018;1(3):1763.</mixed-citation><mixed-citation xml:lang="en">Zhang Y., Ding N., Cao Y., Zhu Z., Gao P. Differential diagnosis between hepatocellular carcinoma and cirrhosis by serum amino acids and acylcarnitines. International Journal of Clinical and Experimental Pathology. 2018;1(3):1763.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Osti D., Del Bene M., Rappa G., Santos M., Matafora V., Richichi C. et al. Clinical significance of extracellular vesicles in plasma from glioblastoma patients. Clinical Cancer Research. 2019;25(1):266–276. DOI: 10.1158/1078-0432.CCR18-1941.</mixed-citation><mixed-citation xml:lang="en">Osti D., Del Bene M., Rappa G., Santos M., Matafora V., Richichi C. et al. Clinical significance of extracellular vesicles in plasma from glioblastoma patients. Clinical Cancer Research. 2019;25(1):266–276. DOI: 10.1158/1078-0432.CCR18-1941.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Jasbi P., Wang D., Cheng S.L., Fei Q., Cui J.Y., Liu L. et al. Breast cancer detection using targeted plasma metabolomics. Journal of Chromatography B. 2019;1105:26–37. DOI: 10.1016/j.jchromb.2018.11.029.</mixed-citation><mixed-citation xml:lang="en">Jasbi P., Wang D., Cheng S.L., Fei Q., Cui J.Y., Liu L. et al. Breast cancer detection using targeted plasma metabolomics. Journal of Chromatography B. 2019;1105:26–37. DOI: 10.1016/j.jchromb.2018.11.029.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Eniu D.T., Romanciuc F., Moraru C., Goidescu I., Eniu D., Staicu A. et al. The decrease of some serum free amino acids can predict breast cancer diagnosis and progression. Scandinavian Journal of Clinical and Laboratory Investigation. 2019;79(1–2):17–24. DOI: 10.1080/00365513.2018.1542541.</mixed-citation><mixed-citation xml:lang="en">Eniu D.T., Romanciuc F., Moraru C., Goidescu I., Eniu D., Staicu A. et al. The decrease of some serum free amino acids can predict breast cancer diagnosis and progression. Scandinavian Journal of Clinical and Laboratory Investigation. 2019;79(1–2):17–24. DOI: 10.1080/00365513.2018.1542541.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Hung C.Y., Yeh T.S., Tsai C.K., Wu R.C., Lai Y.C., Chiang M.H. et al. Glycerophospholipids pathways and chromosomal instability in gastric cancer: Global lipidomics analysis. World Journal of Gastrointestinal Oncology. 2019;11(3):181. DOI: 10.4251/wjgo.v11.i3.181.</mixed-citation><mixed-citation xml:lang="en">Hung C.Y., Yeh T.S., Tsai C.K., Wu R.C., Lai Y.C., Chiang M.H. et al. Glycerophospholipids pathways and chromosomal instability in gastric cancer: Global lipidomics analysis. World Journal of Gastrointestinal Oncology. 2019;11(3):181. DOI: 10.4251/wjgo.v11.i3.181.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Nalbantoglu S., Abu-Asab M., Suy S., Collins S., Amri H. Metabolomics-based biosignatures of prostate cancer in patients following radiotherapy. OMICS: A Journal of Integrative Biology. 2019;23(4):214–223. DOI: 10.1089/omi.2019.0006.</mixed-citation><mixed-citation xml:lang="en">Nalbantoglu S., Abu-Asab M., Suy S., Collins S., Amri H. Metabolomics-based biosignatures of prostate cancer in patients following radiotherapy. OMICS: A Journal of Integrative Biology. 2019;23(4):214–223. DOI: 10.1089/omi.2019.0006.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Harel M., Ortenberg R., Varanasi S.K., Mangalhara K.C., Mardamshina M., Markovits E. et al. Proteomics of melanoma response to immunotherapy reveals mitochondrial dependence. Cell. 2019;179(1):236–250. DOI: 10.1016/j.cell.2019.08.012.</mixed-citation><mixed-citation xml:lang="en">Harel M., Ortenberg R., Varanasi S.K., Mangalhara K.C., Mardamshina M., Markovits E. et al. Proteomics of melanoma response to immunotherapy reveals mitochondrial dependence. Cell. 2019;179(1):236–250. DOI: 10.1016/j.cell.2019.08.012.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Morse N., Jamaspishvili T., Simon D., Patel P.G., Ren K.Y.M., Wang J. et al. Reliable identification of prostate cancer using mass spectrometry metabolomic imaging in needle core biopsies. Laboratory Investigation. 2019;99(10):1561–1571. DOI: 10.1038/s41374-019-0265-2.</mixed-citation><mixed-citation xml:lang="en">Morse N., Jamaspishvili T., Simon D., Patel P.G., Ren K.Y.M., Wang J. et al. Reliable identification of prostate cancer using mass spectrometry metabolomic imaging in needle core biopsies. Laboratory Investigation. 2019;99(10):1561–1571. DOI: 10.1038/s41374-019-0265-2.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Zhou Y., Lih T.M., Pa J., Höt N., Don M., Cao Y.Hu. et al. Proteomic signatures of 16 major types of human cancer reveal universal and cancer-type-specific proteins for the identification of potential therapeutic targets. Journal of Hematology &amp; Oncology. 2020;13:1–15. DOI: 10.1186/s13045-020-01013-x.</mixed-citation><mixed-citation xml:lang="en">Zhou Y., Lih T.M., Pa J., Höt N., Don M., Cao Y.Hu. et al. Proteomic signatures of 16 major types of human cancer reveal universal and cancer-type-specific proteins for the identification of potential therapeutic targets. Journal of Hematology &amp; Oncology. 2020;13:1–15. DOI: 10.1186/s13045-020-01013-x.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Lee Y.R., An K.Y., Jeon J., Kim N.K., Lee J.W., Hong J. et al. Untargeted metabolomics and polyamine profiling in serum before and after surgery in colorectal cancer patients. Metabolites. 2020;10(12):487. DOI: 10.3390/metabo10120487.</mixed-citation><mixed-citation xml:lang="en">Lee Y.R., An K.Y., Jeon J., Kim N.K., Lee J.W., Hong J. et al. Untargeted metabolomics and polyamine profiling in serum before and after surgery in colorectal cancer patients. Metabolites. 2020;10(12):487. DOI: 10.3390/metabo10120487.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Yu D., Xuan Q., Zhang C., Hu C., Li Y., Zhao X. et al. Metabolic alterations related to glioma grading based on metabolomics and lipidomics analyses. Metabolites. 2020;10(12):478. DOI: 10.3390/metabo10120478.</mixed-citation><mixed-citation xml:lang="en">Yu D., Xuan Q., Zhang C., Hu C., Li Y., Zhao X. et al. Metabolic alterations related to glioma grading based on metabolomics and lipidomics analyses. Metabolites. 2020;10(12):478. DOI: 10.3390/metabo10120478.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Vaysse P.M., Kooreman L.F., Engelen S.M., Kremer B., Olde Damink S. W., Heeren R.M. et al. Stromal vapors for real-time molecular guidance of breast-conserving surgery. Scientific Reports. 2020;10(1):20109. DOI: 10.1038/s41598-020-77102-1.</mixed-citation><mixed-citation xml:lang="en">Vaysse P.M., Kooreman L.F., Engelen S.M., Kremer B., Olde Damink S. W., Heeren R.M. et al. Stromal vapors for real-time molecular guidance of breast-conserving surgery. Scientific Reports. 2020;10(1):20109. DOI: 10.1038/s41598-020-77102-1.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Möginger U., Marcussen N., Jensen O.N. Histo-molecular differentiation of renal cancer subtypes by mass spectrometry imaging and rapid proteome profiling of formalin-fixed paraffin-embedded tumor tissue sections. Oncotarget. 2020;11(44):3998. DOI: 10.18632/oncotarget.27787.</mixed-citation><mixed-citation xml:lang="en">Möginger U., Marcussen N., Jensen O.N. Histo-molecular differentiation of renal cancer subtypes by mass spectrometry imaging and rapid proteome profiling of formalin-fixed paraffin-embedded tumor tissue sections. Oncotarget. 2020;11(44):3998. DOI: 10.18632/oncotarget.27787.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Sarbu M., Clemmer D.E., Zamfir A.D. Ion mobility mass spectrometry of human melanoma gangliosides. Biochimie. 2020;177: 26–237. DOI: 10.1016/j.biochi.2020.08.011.</mixed-citation><mixed-citation xml:lang="en">Sarbu M., Clemmer D.E., Zamfir A.D. Ion mobility mass spectrometry of human melanoma gangliosides. Biochimie. 2020;177: 26–237. DOI: 10.1016/j.biochi.2020.08.011.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Chen X., Zhu Y., Jijiwa M., Nasu M., Ai J., Dai S. et al. Identification of plasma lipid species as promising diagnostic markers for prostate cancer. BMC Medical Informatics and Decision Making. 2020;20:1–10. DOI: 10.1186/s12911-020-01242-7.</mixed-citation><mixed-citation xml:lang="en">Chen X., Zhu Y., Jijiwa M., Nasu M., Ai J., Dai S. et al. Identification of plasma lipid species as promising diagnostic markers for prostate cancer. BMC Medical Informatics and Decision Making. 2020;20:1–10. DOI: 10.1186/s12911-020-01242-7.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Noreldeen H.A., Du L., Li W., Liu X., Wang Y., Xu G. Serum lipidomic biomarkers for non-small cell lung cancer in nonsmoking female patients. Journal of Pharmaceutical and Biomedical Analysis. 2020;185:113220. DOI: 10.1016/j.jpba.2020.113220.</mixed-citation><mixed-citation xml:lang="en">Noreldeen H.A., Du L., Li W., Liu X., Wang Y., Xu G. Serum lipidomic biomarkers for non-small cell lung cancer in nonsmoking female patients. Journal of Pharmaceutical and Biomedical Analysis. 2020;185:113220. DOI: 10.1016/j.jpba.2020.113220.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Cheng F., Wen Z., Feng X., Wang X., Chen Y. A serum lipidomic strategy revealed potential lipid biomarkers for early-stage cervical cancer. Life Sciences. 2020;260:118489. DOI: 10.1016/j.lfs.2020.118489.</mixed-citation><mixed-citation xml:lang="en">Cheng F., Wen Z., Feng X., Wang X., Chen Y. A serum lipidomic strategy revealed potential lipid biomarkers for early-stage cervical cancer. Life Sciences. 2020;260:118489. DOI: 10.1016/j.lfs.2020.118489.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">You L., Fan Y., Liu X., Shao S., Guo L., Noreldeen H.A. et al. Liquid chromatography–mass spectrometry-based tissue metabolic profiling reveals major metabolic pathway alterations and potential biomarkers of lung cancer. Journal of Proteome Research. 2020;19(9):3750–3760. DOI: 10.1021/acs.jproteome.0c00285.</mixed-citation><mixed-citation xml:lang="en">You L., Fan Y., Liu X., Shao S., Guo L., Noreldeen H.A. et al. Liquid chromatography–mass spectrometry-based tissue metabolic profiling reveals major metabolic pathway alterations and potential biomarkers of lung cancer. Journal of Proteome Research. 2020;19(9):3750–3760. DOI: 10.1021/acs.jproteome.0c00285.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Kurczyk A., Gawin M., Chekan M., Wilk A., Łakomiec K., Mrukwa G. et al. Classification of thyroid tumors based on mass spectrometry imaging of tissue microarrays; a single-pixel approach. International Journal of Molecular Sciences. 2020;21(17):6289. DOI: 10.3390/ijms21176289.</mixed-citation><mixed-citation xml:lang="en">Kurczyk A., Gawin M., Chekan M., Wilk A., Łakomiec K., Mrukwa G. et al. Classification of thyroid tumors based on mass spectrometry imaging of tissue microarrays; a single-pixel approach. International Journal of Molecular Sciences. 2020;21(17):6289. DOI: 10.3390/ijms21176289.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Zhu N., Xing X., Cao L., Zhang Y., Zhang T., Li Z. et al. Study on the diagnosis of gastric cancer by magnetic beads extraction and mass spectrometry. BioMed Research International. 2020;2020:2743060. DOI: 10.1155/2020/2743060.</mixed-citation><mixed-citation xml:lang="en">Zhu N., Xing X., Cao L., Zhang Y., Zhang T., Li Z. et al. Study on the diagnosis of gastric cancer by magnetic beads extraction and mass spectrometry. BioMed Research International. 2020;2020:2743060. DOI: 10.1155/2020/2743060.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Pekov S. I., Bormotov D. S., Nikitin P. V., Sorokin A. A., Shurkhay V. A., Eliferov V. A. et al. Rapid estimation of tumor cell percentage in brain tissue biopsy samples using inline cartridge extraction mass spectrometry. Analytical and Bioanalytical Chemistry. 2021;413:2913–2922. DOI: 10.1007/s00216-021-03220-y.</mixed-citation><mixed-citation xml:lang="en">Pekov S. I., Bormotov D. S., Nikitin P. V., Sorokin A. A., Shurkhay V. A., Eliferov V. A. et al. Rapid estimation of tumor cell percentage in brain tissue biopsy samples using inline cartridge extraction mass spectrometry. Analytical and Bioanalytical Chemistry. 2021;413:2913–2922. DOI: 10.1007/s00216-021-03220-y.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Liu W., Xie L., He Y.H., Wu Z.Y., Liu L.X., Bai X.F. et al. Large-scale and high-resolution mass spectrometry-based proteomics profiling defines molecular subtypes of esophageal cancer for therapeutic targeting. Nature Communications. 2021;12(1):4961. DOI: 10.1038/s41467-021-25202-5.</mixed-citation><mixed-citation xml:lang="en">Liu W., Xie L., He Y.H., Wu Z.Y., Liu L.X., Bai X.F. et al. Large-scale and high-resolution mass spectrometry-based proteomics profiling defines molecular subtypes of esophageal cancer for therapeutic targeting. Nature Communications. 2021;12(1):4961. DOI: 10.1038/s41467-021-25202-5.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Wei Y., Jasbi P., Shi X., Turner C., Hrovat J., Liu L. et al. Early breast cancer detection using untargeted and targeted metabolomics. Journal of Proteome Research. 2021;20(6):3124–3133. DOI: 10.1021/acs.jproteome.1c00019.</mixed-citation><mixed-citation xml:lang="en">Wei Y., Jasbi P., Shi X., Turner C., Hrovat J., Liu L. et al. Early breast cancer detection using untargeted and targeted metabolomics. Journal of Proteome Research. 2021;20(6):3124–3133. DOI: 10.1021/acs.jproteome.1c00019.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Ecker J., Benedetti E., Kindt A.S., Höring M., Perl M., Machmüller A.C. et al. The colorectal cancer lipidome: identification of a robust tumor-specific lipid species signature. Gastroenterology. 2021;161(3):910–923. DOI: 10.1053/j.gastro.2021.05.009.</mixed-citation><mixed-citation xml:lang="en">Ecker J., Benedetti E., Kindt A.S., Höring M., Perl M., Machmüller A.C. et al. The colorectal cancer lipidome: identification of a robust tumor-specific lipid species signature. Gastroenterology. 2021;161(3):910–923. DOI: 10.1053/j.gastro.2021.05.009.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Li X., Zheng N.R., Wang L.H., Li Z.W., Liu Z.C., Fan H. et al. Proteomic profiling identifies signatures associated with progression of precancerous gastric lesions and risk of early gastric cancer. EBioMedicine. 2021;74. DOI: 10.1016/j.ebiom.2021.103714.</mixed-citation><mixed-citation xml:lang="en">Li X., Zheng N.R., Wang L.H., Li Z.W., Liu Z.C., Fan H. et al. Proteomic profiling identifies signatures associated with progression of precancerous gastric lesions and risk of early gastric cancer. EBioMedicine. 2021;74. DOI: 10.1016/j.ebiom.2021.103714.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Milighetti M., Krasny L., Lee A.T., Morani G., Szecsei C., Chen Y. et al. Proteomic profiling of soft tissue sarcomas with SWATH mass spectrometry. Journal of Proteomics. 2021; 241:104236. DOI: 10.1016/j.jprot.2021.104236.</mixed-citation><mixed-citation xml:lang="en">Milighetti M., Krasny L., Lee A.T., Morani G., Szecsei C., Chen Y. et al. Proteomic profiling of soft tissue sarcomas with SWATH mass spectrometry. Journal of Proteomics. 2021; 241:104236. DOI: 10.1016/j.jprot.2021.104236.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Monsivais D., Vasquez Y.M., Chen F., Zhang Y., Chandrashekar D.S., Faver J.C. et al. Mass-spectrometry-based proteomic correlates of grade and stage reveal pathways and kinases associated with aggressive human cancers. Oncogene. 2021;40(11):2081–2095. DOI: 10.1038/s41388-021-01681-0.</mixed-citation><mixed-citation xml:lang="en">Monsivais D., Vasquez Y.M., Chen F., Zhang Y., Chandrashekar D.S., Faver J.C. et al. Mass-spectrometry-based proteomic correlates of grade and stage reveal pathways and kinases associated with aggressive human cancers. Oncogene. 2021;40(11):2081–2095. DOI: 10.1038/s41388-021-01681-0.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Lima A.R., Carvalho M., Aveiro S.S., Melo T., Domingues M.R., Macedo-Silva C. et al. Comprehensive metabolomics and lipidomics profiling of prostate cancer tissue reveals metabolic dysregulations associated with disease development. Journal of Proteome Research. 2021;21(3):727–739. DOI: 10.1021/acs.jproteome.1c00754.</mixed-citation><mixed-citation xml:lang="en">Lima A.R., Carvalho M., Aveiro S.S., Melo T., Domingues M.R., Macedo-Silva C. et al. Comprehensive metabolomics and lipidomics profiling of prostate cancer tissue reveals metabolic dysregulations associated with disease development. Journal of Proteome Research. 2021;21(3):727–739. DOI: 10.1021/acs.jproteome.1c00754.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Basu S.S., Stopka S.A., Abdelmoula W.M., Randall E.C., Gimenez-Cassina Lopez B., Regan M.S. et al. Interim clinical trial analysis of intraoperative mass spectrometry for breast cancer surgery. NPJ Breast Cancer. 2021;7(1):116. DOI: 10.1038/s41523-021-00318-5.</mixed-citation><mixed-citation xml:lang="en">Basu S.S., Stopka S.A., Abdelmoula W.M., Randall E.C., Gimenez-Cassina Lopez B., Regan M.S. et al. Interim clinical trial analysis of intraoperative mass spectrometry for breast cancer surgery. NPJ Breast Cancer. 2021;7(1):116. DOI: 10.1038/s41523-021-00318-5.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Casadonte R., Kriegsmann M., Kriegsmann K., Hauk I., Meliss R.R., Mueller C.S. et al Imaging mass spectrometry-based proteomic analysis to differentiate melanocytic nevi and malignant melanoma. Cancers. 2021;13(13):3197. DOI: 10.3390/cancers13133197.</mixed-citation><mixed-citation xml:lang="en">Casadonte R., Kriegsmann M., Kriegsmann K., Hauk I., Meliss R.R., Mueller C.S. et al Imaging mass spectrometry-based proteomic analysis to differentiate melanocytic nevi and malignant melanoma. Cancers. 2021;13(13):3197. DOI: 10.3390/cancers13133197.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Brown H.M., Alfaro C.M., Pirro V., Dey M., Hattab E.M., Cohen-Gadol A.A. et al. Cooks R.G. Intraoperative mass spectrometry platform for IDH mutation status prediction, glioma diagnosis, and estimation of tumor cell infiltration. The Journal of Applied Laboratory Medicine. 2021;6(4):902–916. DOI: 10.1093/jalm/jfaa233.</mixed-citation><mixed-citation xml:lang="en">Brown H.M., Alfaro C.M., Pirro V., Dey M., Hattab E.M., Cohen-Gadol A.A. et al. Cooks R.G. Intraoperative mass spectrometry platform for IDH mutation status prediction, glioma diagnosis, and estimation of tumor cell infiltration. The Journal of Applied Laboratory Medicine. 2021;6(4):902–916. DOI: 10.1093/jalm/jfaa233.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Buentzel J., Klemp H.G., Kraetzner R., Schulz M., Dihazi G.H., Streit F. et al. Metabolomic profiling of blood-derived microvesicles in breast cancer patients. International Journal of Molecular Sciences. 2021;22(24):13540. DOI: 10.3390/ijms222413540.</mixed-citation><mixed-citation xml:lang="en">Buentzel J., Klemp H.G., Kraetzner R., Schulz M., Dihazi G.H., Streit F. et al. Metabolomic profiling of blood-derived microvesicles in breast cancer patients. International Journal of Molecular Sciences. 2021;22(24):13540. DOI: 10.3390/ijms222413540.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Răchieriu C., Eniu D.T., Moiş E., Graur F., Socaciu C., Socaciu M.A. et al. Lipidomic signatures for colorectal cancer diagnosis and progression using UPLC-QTOF-ESI+ MS. Biomolecules. 2021;11(3):417. DOI: 10.3390/biom11030417.</mixed-citation><mixed-citation xml:lang="en">Răchieriu C., Eniu D.T., Moiş E., Graur F., Socaciu C., Socaciu M.A. et al. Lipidomic signatures for colorectal cancer diagnosis and progression using UPLC-QTOF-ESI+ MS. Biomolecules. 2021;11(3):417. DOI: 10.3390/biom11030417.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Hashim N.A.A., Ab-Rahim S., Ngah W.Z.W., Nathan S., Ab Mutalib N.S., Sagap I. et al. Global metabolomics profiling of colorectal cancer in Malaysian patients. BioImpacts: BI. 2021; 11(1):33. DOI: 10.34172/bi.2021.05.</mixed-citation><mixed-citation xml:lang="en">Hashim N.A.A., Ab-Rahim S., Ngah W.Z.W., Nathan S., Ab Mutalib N.S., Sagap I. et al. Global metabolomics profiling of colorectal cancer in Malaysian patients. BioImpacts: BI. 2021; 11(1):33. DOI: 10.34172/bi.2021.05.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Butler L.M., Mah C.Y., Machiels J., Vincent A.D., Irani S., Mutuku S.M. et al. Lipidomic profiling of clinical prostate cancer reveals targetable alterations in membrane lipid composition. Cancer Research. 2021;81(19):4981–4993. DOI: 10.1158/0008-5472.CAN-20-3863.</mixed-citation><mixed-citation xml:lang="en">Butler L.M., Mah C.Y., Machiels J., Vincent A.D., Irani S., Mutuku S.M. et al. Lipidomic profiling of clinical prostate cancer reveals targetable alterations in membrane lipid composition. Cancer Research. 2021;81(19):4981–4993. DOI: 10.1158/0008-5472.CAN-20-3863.</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Chen F., Dai X., Zhou C.C., Li K.X., Zhang Y.J., Lou X.Y. et al. Integrated analysis of the faecal metagenome and serum metabolome reveals the role of gut microbiome-associated metabolites in the detection of colorectal cancer and adenoma. Gut. 2022;71(7):1315–1325. DOI: 10.1136/gutjnl-2020-323476.</mixed-citation><mixed-citation xml:lang="en">Chen F., Dai X., Zhou C.C., Li K.X., Zhang Y.J., Lou X.Y. et al. Integrated analysis of the faecal metagenome and serum metabolome reveals the role of gut microbiome-associated metabolites in the detection of colorectal cancer and adenoma. Gut. 2022;71(7):1315–1325. DOI: 10.1136/gutjnl-2020-323476.</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Wolrab D., Jirásko R., Cífková E., Höring M., Mei D., Chocholoušková M. et al Lipidomic profiling of human serum enables detection of pancreatic cancer. Nature Communications. 2022;13(1):124. DOI: 10.1038/s41467-021-27765-9.</mixed-citation><mixed-citation xml:lang="en">Wolrab D., Jirásko R., Cífková E., Höring M., Mei D., Chocholoušková M. et al Lipidomic profiling of human serum enables detection of pancreatic cancer. Nature Communications. 2022;13(1):124. DOI: 10.1038/s41467-021-27765-9.</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Soltis A.R., Bateman N.W., Liu J., Nguyen T., Franks T.J., Zhang X. et al. Proteogenomic analysis of lung adenocarcinoma reveals tumor heterogeneity, survival determinants, and therapeutically relevant pathways. Cell Reports Medicine. 2022;3(11). DOI: 10.1016/j.xcrm.2022.100819.</mixed-citation><mixed-citation xml:lang="en">Soltis A.R., Bateman N.W., Liu J., Nguyen T., Franks T.J., Zhang X. et al. Proteogenomic analysis of lung adenocarcinoma reveals tumor heterogeneity, survival determinants, and therapeutically relevant pathways. Cell Reports Medicine. 2022;3(11). DOI: 10.1016/j.xcrm.2022.100819.</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Li Y., Jiang L., Wang Z., Wang Y., Cao X., Meng L. et al. Profiling of urine carbonyl metabolic fingerprints in bladder cancer based on ambient ionization mass spectrometry. Analytical Chemistry. 2022;94(27):9894–9902. DOI: 10.1021/acs.analchem.2c01890.</mixed-citation><mixed-citation xml:lang="en">Li Y., Jiang L., Wang Z., Wang Y., Cao X., Meng L. et al. Profiling of urine carbonyl metabolic fingerprints in bladder cancer based on ambient ionization mass spectrometry. Analytical Chemistry. 2022;94(27):9894–9902. DOI: 10.1021/acs.analchem.2c01890.</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Alvarez M.R.S., Zhou Q., Tena J., Lebrilla C.B., Completo G.C., Heralde III F.M. et al. N-Glycan and glycopeptide serum biomarkers in philippine lung cancer patients identified using liquid chromatography-tandem mass gpectrometry. ACS Omega. 2022;7(44):40230–40240. DOI: 10.1021/acsomega.2c05111.</mixed-citation><mixed-citation xml:lang="en">Alvarez M.R.S., Zhou Q., Tena J., Lebrilla C.B., Completo G.C., Heralde III F.M. et al. N-Glycan and glycopeptide serum biomarkers in philippine lung cancer patients identified using liquid chromatography-tandem mass gpectrometry. ACS Omega. 2022;7(44):40230–40240. DOI: 10.1021/acsomega.2c05111.</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Blaschke C.R., Hill E.G., Mehta A.S., Angel P.M., Laronga C., Drake R.R. Integrating age, BMI, and serum N-glycans detected by MALDI mass spectrometry to classify suspicious mammogram findings as benign lesions or breast cancer. Scientific Reports. 2022;12(1):20801. DOI: 10.1038/s41598-022-25401-0.</mixed-citation><mixed-citation xml:lang="en">Blaschke C.R., Hill E.G., Mehta A.S., Angel P.M., Laronga C., Drake R.R. Integrating age, BMI, and serum N-glycans detected by MALDI mass spectrometry to classify suspicious mammogram findings as benign lesions or breast cancer. Scientific Reports. 2022;12(1):20801. DOI: 10.1038/s41598-022-25401-0.</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Wang X., Li H., Zou X., Yan X., Cong P., Li H. et al. Deep mining and quantification of oxidized cholesteryl esters discovers potential biomarkers involved in breast cancer by liquid chromatography-mass spectrometry. Journal of Chromatography A. 2022;1663:462764. DOI: 10.1016/j.chroma.2021.462764.</mixed-citation><mixed-citation xml:lang="en">Wang X., Li H., Zou X., Yan X., Cong P., Li H. et al. Deep mining and quantification of oxidized cholesteryl esters discovers potential biomarkers involved in breast cancer by liquid chromatography-mass spectrometry. Journal of Chromatography A. 2022;1663:462764. DOI: 10.1016/j.chroma.2021.462764.</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Östman J.R., Pinto R.C., Ebbels T.M., Thysell E., Hallmans G., Moazzami A.A. Identification of prediagnostic metabolites associated with prostate cancer risk by untargeted mass spectrometry‐based metabolomics: A case‐control study nested in the Northern Sweden Health and Disease Study. International Journal of Cancer. 2022;151(12):2115–2127. DOI: 10.1002/ijc.34223.</mixed-citation><mixed-citation xml:lang="en">Östman J.R., Pinto R.C., Ebbels T.M., Thysell E., Hallmans G., Moazzami A.A. Identification of prediagnostic metabolites associated with prostate cancer risk by untargeted mass spectrometry‐based metabolomics: A case‐control study nested in the Northern Sweden Health and Disease Study. International Journal of Cancer. 2022;151(12):2115–2127. DOI: 10.1002/ijc.34223.</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Sommella E., Salviati E., Caponigro V., Grimaldi M., Musella S., Bertamino A. et al. MALDI Mass Spectrometry Imaging highlights specific metabolome and lipidome profiles in salivary gland tumor tissues. Metabolites. 2022;12(6):530. DOI: 10.3390/metabo12060530.</mixed-citation><mixed-citation xml:lang="en">Sommella E., Salviati E., Caponigro V., Grimaldi M., Musella S., Bertamino A. et al. MALDI Mass Spectrometry Imaging highlights specific metabolome and lipidome profiles in salivary gland tumor tissues. Metabolites. 2022;12(6):530. DOI: 10.3390/metabo12060530.</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Bogusiewicz J., Gaca-Tabaszewska M., Olszówka D., Jaroch K., Furtak J., Harat M. et al. Coated blade spray-mass spectrometry as a new approach for the rapid characterization of brain tumors. Molecules. 2022;27(7):2251. DOI: 10.3390/molecules27072251.</mixed-citation><mixed-citation xml:lang="en">Bogusiewicz J., Gaca-Tabaszewska M., Olszówka D., Jaroch K., Furtak J., Harat M. et al. Coated blade spray-mass spectrometry as a new approach for the rapid characterization of brain tumors. Molecules. 2022;27(7):2251. DOI: 10.3390/molecules27072251.</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Huang J., Zhao B., Weinstein S.J., Albanes D., Mondul A.M. Metabolomic profile of prostate cancer-specific survival among 1812 Finnish men. BMC Medicine. 2022;20(1):1–13. DOI: 10.1186/s12916-022-02561-4.</mixed-citation><mixed-citation xml:lang="en">Huang J., Zhao B., Weinstein S.J., Albanes D., Mondul A.M. Metabolomic profile of prostate cancer-specific survival among 1812 Finnish men. BMC Medicine. 2022;20(1):1–13. DOI: 10.1186/s12916-022-02561-4.</mixed-citation></citation-alternatives></ref><ref id="cit61"><label>61</label><citation-alternatives><mixed-citation xml:lang="ru">Maslov D.L., Trifonova O.P., Lichtenberg S., Balashova E.E., Mamedli Z.Z., Alferov A.A. et al. Blood plasma metabolome profiling at different stages of renal cell carcinoma. Cancers. 2022;15(1):140. DOI: 10.3390/cancers15010140.</mixed-citation><mixed-citation xml:lang="en">Maslov D.L., Trifonova O.P., Lichtenberg S., Balashova E.E., Mamedli Z.Z., Alferov A.A. et al. Blood plasma metabolome profiling at different stages of renal cell carcinoma. Cancers. 2022;15(1):140. DOI: 10.3390/cancers15010140.</mixed-citation></citation-alternatives></ref><ref id="cit62"><label>62</label><citation-alternatives><mixed-citation xml:lang="ru">Huang L., Mao X., Sun C., Li T., Song X., Li J. et al. Molecular pathological diagnosis of thyroid tumors using spatially resolved metabolomics. Molecules. 2022;27(4):1390. DOI: 10.3390/molecules27041390.</mixed-citation><mixed-citation xml:lang="en">Huang L., Mao X., Sun C., Li T., Song X., Li J. et al. Molecular pathological diagnosis of thyroid tumors using spatially resolved metabolomics. Molecules. 2022;27(4):1390. DOI: 10.3390/molecules27041390.</mixed-citation></citation-alternatives></ref><ref id="cit63"><label>63</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang L.H., Zhuo H.Q., Hou J.J., Zhou Y., Cheng J., Cai J.C. Proteomic signatures of infiltrative gastric cancer by proteomic and bioinformatic analysis. World Journal of Gastrointestinal Oncology. 2022;14(11):2097. DOI: 10.4251/wjgo.v14.i11.2097.</mixed-citation><mixed-citation xml:lang="en">Zhang L.H., Zhuo H.Q., Hou J.J., Zhou Y., Cheng J., Cai J.C. Proteomic signatures of infiltrative gastric cancer by proteomic and bioinformatic analysis. World Journal of Gastrointestinal Oncology. 2022;14(11):2097. DOI: 10.4251/wjgo.v14.i11.2097.</mixed-citation></citation-alternatives></ref><ref id="cit64"><label>64</label><citation-alternatives><mixed-citation xml:lang="ru">Luo Q., Liu J., Fu Q., Zhang X., Yu P., Liu P. et al. Identifying cancer cell‐secreted proteins that activate cancer‐associated fibroblasts as prognostic factors for patients with pancreatic cancer. Journal of Cellular and Molecular Medicine. 2022;26(22):5657–5669. DOI: 10.1111/jcmm.17596.</mixed-citation><mixed-citation xml:lang="en">Luo Q., Liu J., Fu Q., Zhang X., Yu P., Liu P. et al. Identifying cancer cell‐secreted proteins that activate cancer‐associated fibroblasts as prognostic factors for patients with pancreatic cancer. Journal of Cellular and Molecular Medicine. 2022;26(22):5657–5669. DOI: 10.1111/jcmm.17596.</mixed-citation></citation-alternatives></ref><ref id="cit65"><label>65</label><citation-alternatives><mixed-citation xml:lang="ru">Hwang B.Y., Seo J.W., Muftuoglu C., Mert U., Guldaval F., Asadi M. et al. Salivary lipids of patients with non-small cell lung cancer show perturbation with respect to plasma. International Journal of Molecular Sciences. 2023;24(18):14264. DOI: 10.3390/ijms241814264.</mixed-citation><mixed-citation xml:lang="en">Hwang B.Y., Seo J.W., Muftuoglu C., Mert U., Guldaval F., Asadi M. et al. Salivary lipids of patients with non-small cell lung cancer show perturbation with respect to plasma. International Journal of Molecular Sciences. 2023;24(18):14264. DOI: 10.3390/ijms241814264.</mixed-citation></citation-alternatives></ref><ref id="cit66"><label>66</label><citation-alternatives><mixed-citation xml:lang="ru">Stanojevic A., Samiotaki M., Lygirou V., Marinkovic M., Nikolic V., Stojanovic-Rundic S. et al. Data-independent acquisition mass spectrometry analysis of FFPE rectal cancer samples offers in-depth proteomics characterization of the response to neoadjuvant chemoradiotherapy. International Journal of Molecular Sciences. 2023;24(20):15412. DOI: 10.3390/ijms242015412</mixed-citation><mixed-citation xml:lang="en">Stanojevic A., Samiotaki M., Lygirou V., Marinkovic M., Nikolic V., Stojanovic-Rundic S. et al. Data-independent acquisition mass spectrometry analysis of FFPE rectal cancer samples offers in-depth proteomics characterization of the response to neoadjuvant chemoradiotherapy. International Journal of Molecular Sciences. 2023;24(20):15412. DOI: 10.3390/ijms242015412</mixed-citation></citation-alternatives></ref><ref id="cit67"><label>67</label><citation-alternatives><mixed-citation xml:lang="ru">Pietkiewicz D., Zaborowski M.P., Jaz K., Matuszewska E., Światły-Błaszkiewicz A., Kluz T. et al. Serum proteomic profiles of patients with high and low risk of endometrial cancer recurrence. International Journal of Molecular Sciences. 2023;24(19):14528. DOI: 10.3390/ijms241914528.</mixed-citation><mixed-citation xml:lang="en">Pietkiewicz D., Zaborowski M.P., Jaz K., Matuszewska E., Światły-Błaszkiewicz A., Kluz T. et al. Serum proteomic profiles of patients with high and low risk of endometrial cancer recurrence. International Journal of Molecular Sciences. 2023;24(19):14528. DOI: 10.3390/ijms241914528.</mixed-citation></citation-alternatives></ref><ref id="cit68"><label>68</label><citation-alternatives><mixed-citation xml:lang="ru">Wang J., Saltzman A.B., Jaehnig E.J., Lei J.T., Malovannaya A., Holt M.V. et al. Kinase inhibitor pulldown assay identifies a chemotherapy response signature in triple-negative breast cancer based on purine-binding proteins. Cancer Research Communications. 2023;3(8):1551–1563. DOI: 10.1158/2767-9764.CRC-22-0501.</mixed-citation><mixed-citation xml:lang="en">Wang J., Saltzman A.B., Jaehnig E.J., Lei J.T., Malovannaya A., Holt M.V. et al. Kinase inhibitor pulldown assay identifies a chemotherapy response signature in triple-negative breast cancer based on purine-binding proteins. Cancer Research Communications. 2023;3(8):1551–1563. DOI: 10.1158/2767-9764.CRC-22-0501.</mixed-citation></citation-alternatives></ref><ref id="cit69"><label>69</label><citation-alternatives><mixed-citation xml:lang="ru">Yamashita T., Takanashi Y., Uebayashi A., Oka M., Mizuno K., Kawase A. et al. Lung adenocarcinoma and squamous cell carcinoma difficult for immunohistochemical diagnosis can be distinguished by lipid profile. Scientific Reports. 2023;13(1):12092. DOI: 10.1038/s41598-023-37848-w.</mixed-citation><mixed-citation xml:lang="en">Yamashita T., Takanashi Y., Uebayashi A., Oka M., Mizuno K., Kawase A. et al. Lung adenocarcinoma and squamous cell carcinoma difficult for immunohistochemical diagnosis can be distinguished by lipid profile. Scientific Reports. 2023;13(1):12092. DOI: 10.1038/s41598-023-37848-w.</mixed-citation></citation-alternatives></ref><ref id="cit70"><label>70</label><citation-alternatives><mixed-citation xml:lang="ru">Dunphy K., Bazou D., Henry M., Meleady P., Miettinen J.J., Heckman C.A. et al. Proteomic and metabolomic analysis of bone marrow and plasma from patients with extramedullary multiple myeloma identifies distinct protein and metabolite signatures. Cancers. 2023;15(15):3764. DOI: 10.3390/cancers15153764.</mixed-citation><mixed-citation xml:lang="en">Dunphy K., Bazou D., Henry M., Meleady P., Miettinen J.J., Heckman C.A. et al. Proteomic and metabolomic analysis of bone marrow and plasma from patients with extramedullary multiple myeloma identifies distinct protein and metabolite signatures. Cancers. 2023;15(15):3764. DOI: 10.3390/cancers15153764.</mixed-citation></citation-alternatives></ref><ref id="cit71"><label>71</label><citation-alternatives><mixed-citation xml:lang="ru">Kocsmar E., Schmid M., Cosenza-Contreras M., Kocsmar I., Foll M., Krey L. et al. Proteome alterations in human autopsy tissues in relation to time after death. Cellular and Molecular Life Sciences. 2023;80(5):117. DOI: 10.1007/s00018-023-04754-3.</mixed-citation><mixed-citation xml:lang="en">Kocsmar E., Schmid M., Cosenza-Contreras M., Kocsmar I., Foll M., Krey L. et al. Proteome alterations in human autopsy tissues in relation to time after death. Cellular and Molecular Life Sciences. 2023;80(5):117. DOI: 10.1007/s00018-023-04754-3.</mixed-citation></citation-alternatives></ref><ref id="cit72"><label>72</label><citation-alternatives><mixed-citation xml:lang="ru">Cao L., Huang C., Zhou D.C., Hu Y., Lih T.M., Savage S.R. et al. Proteogenomic characterization of pancreatic ductal adenocarcinoma. Cell. 2021;184(19):5031–5052. DOI: 10.1016/j.cell.2021.08.023.</mixed-citation><mixed-citation xml:lang="en">Cao L., Huang C., Zhou D.C., Hu Y., Lih T.M., Savage S.R. et al. Proteogenomic characterization of pancreatic ductal adenocarcinoma. Cell. 2021;184(19):5031–5052. DOI: 10.1016/j.cell.2021.08.023.</mixed-citation></citation-alternatives></ref><ref id="cit73"><label>73</label><citation-alternatives><mixed-citation xml:lang="ru">Pekov S.I., Sorokin A.A., Kuzin A.A., Bocharov K.V., Bormotov D.S., Shivalin A.S. et al. Analysis of phosphatidylcholines alterations in human glioblastomas ex vivo. Biomeditsinskaia Khimiia. 2021;15(3):241–247. DOI: 10.18097/PBMC20216701081.</mixed-citation><mixed-citation xml:lang="en">Pekov S.I., Sorokin A.A., Kuzin A.A., Bocharov K.V., Bormotov D.S., Shivalin A.S. et al. Analysis of phosphatidylcholines alterations in human glioblastomas ex vivo. Biomeditsinskaia Khimiia. 2021;15(3):241–247. DOI: 10.18097/PBMC20216701081.</mixed-citation></citation-alternatives></ref><ref id="cit74"><label>74</label><citation-alternatives><mixed-citation xml:lang="ru">Torres-de la Roche L.A., Acevedo-Mesa A., Lizarazo I. L., Devassy R., Becker S. et al. Hormonal Contraception and the Risk of Breast Cancer in Women of Reproductive Age: A Meta-Analysis. Cancers. 2023;15(23):5624. DOI: 10.3390/cancers15235624.</mixed-citation><mixed-citation xml:lang="en">Torres-de la Roche L.A., Acevedo-Mesa A., Lizarazo I. L., Devassy R., Becker S. et al. Hormonal Contraception and the Risk of Breast Cancer in Women of Reproductive Age: A Meta-Analysis. Cancers. 2023;15(23):5624. DOI: 10.3390/cancers15235624.</mixed-citation></citation-alternatives></ref><ref id="cit75"><label>75</label><citation-alternatives><mixed-citation xml:lang="ru">Onyije F.M., Dolatkhah R., Olsson A., Bouaoun L., Deltour I., Erdmann F. et al. Risk factors for childhood brain tumours: A systematic review and meta-analysis of observational studies from 1976 to 2022. Cancer Epidemiology. 2024;88:102510. DOI: 10.1016/j.canep.2023.102510.</mixed-citation><mixed-citation xml:lang="en">Onyije F.M., Dolatkhah R., Olsson A., Bouaoun L., Deltour I., Erdmann F. et al. Risk factors for childhood brain tumours: A systematic review and meta-analysis of observational studies from 1976 to 2022. Cancer Epidemiology. 2024;88:102510. DOI: 10.1016/j.canep.2023.102510.</mixed-citation></citation-alternatives></ref><ref id="cit76"><label>76</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang J., Sans M., Garza K.Y., Eberlin L.S. Mass spectrometry technologies to advance care for cancer patients in clinical and intraoperative use. Mass Spectrometry Reviews. 2021;40(5):692–720. DOI: 10.1002/mas.21664.</mixed-citation><mixed-citation xml:lang="en">Zhang J., Sans M., Garza K.Y., Eberlin L.S. Mass spectrometry technologies to advance care for cancer patients in clinical and intraoperative use. Mass Spectrometry Reviews. 2021;40(5):692–720. DOI: 10.1002/mas.21664.</mixed-citation></citation-alternatives></ref><ref id="cit77"><label>77</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang L.H., Zhuo H.Q., Hou J.J., Zhou Y., Cheng J., Cai J.C. Proteomic signatures of infiltrative gastric cancer by proteomic and bioinformatic analysis. World Journal of Gastrointestinal Oncology. 2022;14(11):2097. DOI: 10.4251/wjgo.v14.i11.2097.</mixed-citation><mixed-citation xml:lang="en">Zhang L.H., Zhuo H.Q., Hou J.J., Zhou Y., Cheng J., Cai J.C. Proteomic signatures of infiltrative gastric cancer by proteomic and bioinformatic analysis. World Journal of Gastrointestinal Oncology. 2022;14(11):2097. DOI: 10.4251/wjgo.v14.i11.2097.</mixed-citation></citation-alternatives></ref><ref id="cit78"><label>78</label><citation-alternatives><mixed-citation xml:lang="ru">Elmallah M.I., Ortega‐Deballon P., Hermite L., Pais‐De‐Barros J. P., Gobbo J., Garrido C. Lipidomic profiling of exosomes from colorectal cancer cells and patients reveals potential biomarkers. Molecular Oncology. 2022;16(14):2710–2718. DOI: 10.1002/1878-0261.13223.</mixed-citation><mixed-citation xml:lang="en">Elmallah M.I., Ortega‐Deballon P., Hermite L., Pais‐De‐Barros J. P., Gobbo J., Garrido C. Lipidomic profiling of exosomes from colorectal cancer cells and patients reveals potential biomarkers. Molecular Oncology. 2022;16(14):2710–2718. DOI: 10.1002/1878-0261.13223.</mixed-citation></citation-alternatives></ref><ref id="cit79"><label>79</label><citation-alternatives><mixed-citation xml:lang="ru">Sommella E., Salviati E., Caponigro V., Grimaldi M., Musella S., Bertamino A. et al. MALDI Mass Spectrometry Imaging highlights specific metabolome and lipidome profiles in salivary gland tumor tissues. Metabolites. 2022;12(6):530. DOI: 10.3390/metabo12060530.</mixed-citation><mixed-citation xml:lang="en">Sommella E., Salviati E., Caponigro V., Grimaldi M., Musella S., Bertamino A. et al. MALDI Mass Spectrometry Imaging highlights specific metabolome and lipidome profiles in salivary gland tumor tissues. Metabolites. 2022;12(6):530. DOI: 10.3390/metabo12060530.</mixed-citation></citation-alternatives></ref><ref id="cit80"><label>80</label><citation-alternatives><mixed-citation xml:lang="ru">Blaschke C.R., Hill E.G., Mehta A.S., Angel P.M., Laronga C., Drake R.R. Integrating age, BMI, and serum N-glycans detected by MALDI mass spectrometry to classify suspicious mammogram findings as benign lesions or breast cancer. Scientific Reports. 2022;12(1):20801. DOI: 10.1038/s41598-022-25401-0.</mixed-citation><mixed-citation xml:lang="en">Blaschke C.R., Hill E.G., Mehta A.S., Angel P.M., Laronga C., Drake R.R. Integrating age, BMI, and serum N-glycans detected by MALDI mass spectrometry to classify suspicious mammogram findings as benign lesions or breast cancer. Scientific Reports. 2022;12(1):20801. DOI: 10.1038/s41598-022-25401-0.</mixed-citation></citation-alternatives></ref><ref id="cit81"><label>81</label><citation-alternatives><mixed-citation xml:lang="ru">Fowler K.T., Hugh-Jones P. Mass spectrometry applied to clinical practice and research. British Medical Journal. 1957;1(5029):1205. DOI: 10.1136/bmj.1.5029.1205.</mixed-citation><mixed-citation xml:lang="en">Fowler K.T., Hugh-Jones P. Mass spectrometry applied to clinical practice and research. British Medical Journal. 1957;1(5029):1205. DOI: 10.1136/bmj.1.5029.1205.</mixed-citation></citation-alternatives></ref><ref id="cit82"><label>82</label><citation-alternatives><mixed-citation xml:lang="ru">Cotter R.J. Time-of-flight mass spectrometry for the structural analysis of biological molecules. Analytical Chemistry. 1992;64(21):1027A–1039A. DOI: 10.1021/ac00045a002.</mixed-citation><mixed-citation xml:lang="en">Cotter R.J. Time-of-flight mass spectrometry for the structural analysis of biological molecules. Analytical Chemistry. 1992;64(21):1027A–1039A. DOI: 10.1021/ac00045a002.</mixed-citation></citation-alternatives></ref><ref id="cit83"><label>83</label><citation-alternatives><mixed-citation xml:lang="ru">Bryden W.A., Benson R.C., Echelberger S.A., Phillips T.E., Cotter R.J., Fenselau C. The tiny-TOF mass spectrometer for chemical and biological sensing. Johns Hopkins APL Technical Digest. 1995;16(3):296–310. DOI: 10.1007/978-94-015-9534-6_10.</mixed-citation><mixed-citation xml:lang="en">Bryden W.A., Benson R.C., Echelberger S.A., Phillips T.E., Cotter R.J., Fenselau C. The tiny-TOF mass spectrometer for chemical and biological sensing. Johns Hopkins APL Technical Digest. 1995;16(3):296–310. DOI: 10.1007/978-94-015-9534-6_10.</mixed-citation></citation-alternatives></ref><ref id="cit84"><label>84</label><citation-alternatives><mixed-citation xml:lang="ru">Rifai N., Horvath A. R., Wittwer C.T., Hoofnagle A. Principles and applications of clinical mass spectrometry: small molecules, peptides, and pathogens. Elsevier, 2018.</mixed-citation><mixed-citation xml:lang="en">Rifai N., Horvath A. R., Wittwer C.T., Hoofnagle A. Principles and applications of clinical mass spectrometry: small molecules, peptides, and pathogens. Elsevier, 2018.</mixed-citation></citation-alternatives></ref><ref id="cit85"><label>85</label><citation-alternatives><mixed-citation xml:lang="ru">Raćkowska E., Bobrowska-Korczak B., Giebułtowicz J. Development and validation of a rapid LC–MS/MS method for determination of methylated nucleosides and nucleobases in urine. Journal of Chromatography B. 2019;1128:121775. DOI: 10.1016/j.jchromb.2019.121775.</mixed-citation><mixed-citation xml:lang="en">Raćkowska E., Bobrowska-Korczak B., Giebułtowicz J. Development and validation of a rapid LC–MS/MS method for determination of methylated nucleosides and nucleobases in urine. Journal of Chromatography B. 2019;1128:121775. DOI: 10.1016/j.jchromb.2019.121775.</mixed-citation></citation-alternatives></ref><ref id="cit86"><label>86</label><citation-alternatives><mixed-citation xml:lang="ru">Drake R.R., McDowell C., West C., David F., Powers T.W., Nowling T. et al. Defining the human kidney N‐glycome in normal and cancer tissues using MALDI imaging mass spectrometry. Journal of Mass Spectrometry. 2020;55(4):e4490. DOI: 10.1002/jms.4490.</mixed-citation><mixed-citation xml:lang="en">Drake R.R., McDowell C., West C., David F., Powers T.W., Nowling T. et al. Defining the human kidney N‐glycome in normal and cancer tissues using MALDI imaging mass spectrometry. Journal of Mass Spectrometry. 2020;55(4):e4490. DOI: 10.1002/jms.4490.</mixed-citation></citation-alternatives></ref><ref id="cit87"><label>87</label><citation-alternatives><mixed-citation xml:lang="ru">Takats Z., Strittmatter N., McKenzie J.S. Ambient mass spectrometry in cancer research. Advances in Cancer Research. 2017;134:231–256. DOI: 10.1016/bs.acr.2016.11.011.</mixed-citation><mixed-citation xml:lang="en">Takats Z., Strittmatter N., McKenzie J.S. Ambient mass spectrometry in cancer research. Advances in Cancer Research. 2017;134:231–256. DOI: 10.1016/bs.acr.2016.11.011.</mixed-citation></citation-alternatives></ref><ref id="cit88"><label>88</label><citation-alternatives><mixed-citation xml:lang="ru">Jarmusch A.K., Pirro V., Baird Z., Hattab E.M., Cohen-Gadol A.A., Cooks R.G. Lipid and metabolite profiles of human brain tumors by desorption electrospray ionization-MS. Proceedings of the National Academy of Sciences. 2016;113(6):1486–1491. DOI: 10.1073/pnas.1523306113.</mixed-citation><mixed-citation xml:lang="en">Jarmusch A.K., Pirro V., Baird Z., Hattab E.M., Cohen-Gadol A.A., Cooks R.G. Lipid and metabolite profiles of human brain tumors by desorption electrospray ionization-MS. Proceedings of the National Academy of Sciences. 2016;113(6):1486–1491. DOI: 10.1073/pnas.1523306113.</mixed-citation></citation-alternatives></ref><ref id="cit89"><label>89</label><citation-alternatives><mixed-citation xml:lang="ru">Tillner J., Wu V., Jones E.A., Pringle S.D., Karancsi T., Dannhorn A. et al. Faster, more reproducible DESI-MS for biological tissue imaging. Journal of the American Society for Mass Spectrometry. 2017;28(10):2090–2098. DOI: 10.1007/s13361-017-1714-z.</mixed-citation><mixed-citation xml:lang="en">Tillner J., Wu V., Jones E.A., Pringle S.D., Karancsi T., Dannhorn A. et al. Faster, more reproducible DESI-MS for biological tissue imaging. Journal of the American Society for Mass Spectrometry. 2017;28(10):2090–2098. DOI: 10.1007/s13361-017-1714-z.</mixed-citation></citation-alternatives></ref><ref id="cit90"><label>90</label><citation-alternatives><mixed-citation xml:lang="ru">Kaushal A., Kaur N., Sharma S., Sharma A.K., Kala D., Prakash H. et al. Current update on biomarkers for detection of cancer: comprehensive analysis. Vaccines. 2022;10(12):2138. DOI: 10.3390/vaccines10122138.</mixed-citation><mixed-citation xml:lang="en">Kaushal A., Kaur N., Sharma S., Sharma A.K., Kala D., Prakash H. et al. Current update on biomarkers for detection of cancer: comprehensive analysis. Vaccines. 2022;10(12):2138. DOI: 10.3390/vaccines10122138.</mixed-citation></citation-alternatives></ref><ref id="cit91"><label>91</label><citation-alternatives><mixed-citation xml:lang="ru">Khan H., Shah M.R., Barek J., Malik M.I. Cancer biomarkers and their biosensors: A comprehensive review. TrAC Trends in Analytical Chemistry. 2023;158:116813. DOI: 10.1016/j.trac.2022.116813.</mixed-citation><mixed-citation xml:lang="en">Khan H., Shah M.R., Barek J., Malik M.I. Cancer biomarkers and their biosensors: A comprehensive review. TrAC Trends in Analytical Chemistry. 2023;158:116813. DOI: 10.1016/j.trac.2022.116813.</mixed-citation></citation-alternatives></ref><ref id="cit92"><label>92</label><citation-alternatives><mixed-citation xml:lang="ru">Luo Q., Liu J., Fu Q., Zhang X., Yu P., Liu P. et al. Identifying cancer cell‐secreted proteins that activate cancer‐associated fibroblasts as prognostic factors for patients with pancreatic cancer. Journal of Cellular and Molecular Medicine. 2022;26(22):5657–5669. DOI: 10.1111/jcmm.17596.</mixed-citation><mixed-citation xml:lang="en">Luo Q., Liu J., Fu Q., Zhang X., Yu P., Liu P. et al. Identifying cancer cell‐secreted proteins that activate cancer‐associated fibroblasts as prognostic factors for patients with pancreatic cancer. Journal of Cellular and Molecular Medicine. 2022;26(22):5657–5669. DOI: 10.1111/jcmm.17596.</mixed-citation></citation-alternatives></ref><ref id="cit93"><label>93</label><citation-alternatives><mixed-citation xml:lang="ru">Zhu Z. J., Qi Z., Zhang J., Xue W.H., Li L.F., Shen Z.B. et al. Untargeted metabolomics analysis of esophageal squamous cell carcinoma discovers dysregulated metabolic pathways and potential diagnostic biomarkers. Journal of Cancer. 2020;11(13):3944. DOI: 10.7150/jca.41733.</mixed-citation><mixed-citation xml:lang="en">Zhu Z. J., Qi Z., Zhang J., Xue W.H., Li L.F., Shen Z.B. et al. Untargeted metabolomics analysis of esophageal squamous cell carcinoma discovers dysregulated metabolic pathways and potential diagnostic biomarkers. Journal of Cancer. 2020;11(13):3944. DOI: 10.7150/jca.41733.</mixed-citation></citation-alternatives></ref><ref id="cit94"><label>94</label><citation-alternatives><mixed-citation xml:lang="ru">Pinu F.R., Beale D.J., Paten A.M., Kouremenos K., Swarup S., Schirra H.J. et al. Systems biology and multi-omics integration: viewpoints from the metabolomics research community. Metabolites. 2019;9(4):76. DOI: 10.3390/metabo9040076.</mixed-citation><mixed-citation xml:lang="en">Pinu F.R., Beale D.J., Paten A.M., Kouremenos K., Swarup S., Schirra H.J. et al. Systems biology and multi-omics integration: viewpoints from the metabolomics research community. Metabolites. 2019;9(4):76. DOI: 10.3390/metabo9040076.</mixed-citation></citation-alternatives></ref><ref id="cit95"><label>95</label><citation-alternatives><mixed-citation xml:lang="ru">Schmidt D.R., Patel R., Kirsch D.G., Lewis C.A., Vander Heiden M.G., Locasale J.W. Metabolomics in cancer research and emerging applications in clinical oncology. CA: Cancer Journal for Clinicians. 2021;71(4):333–358. DOI: 10.3322/caac.21670.</mixed-citation><mixed-citation xml:lang="en">Schmidt D.R., Patel R., Kirsch D.G., Lewis C.A., Vander Heiden M.G., Locasale J.W. Metabolomics in cancer research and emerging applications in clinical oncology. CA: Cancer Journal for Clinicians. 2021;71(4):333–358. DOI: 10.3322/caac.21670.</mixed-citation></citation-alternatives></ref><ref id="cit96"><label>96</label><citation-alternatives><mixed-citation xml:lang="ru">Pandey N., Lanke V., Vinod P.K. Network-based metabolic characterization of renal cell carcinoma. Scientific Reports. 2020;10(1):5955. DOI: 10.1038/s41598-020-62853-8.</mixed-citation><mixed-citation xml:lang="en">Pandey N., Lanke V., Vinod P.K. Network-based metabolic characterization of renal cell carcinoma. Scientific Reports. 2020;10(1):5955. DOI: 10.1038/s41598-020-62853-8.</mixed-citation></citation-alternatives></ref><ref id="cit97"><label>97</label><citation-alternatives><mixed-citation xml:lang="ru">Mollica V., Santoni M., Matrana M.R., Basso U., De Giorgi U., Rizzo A. et al. Concomitant proton pump inhibitors and outcome of patients treated with nivolumab alone or plus ipilimumab for advanced renal cell carcinoma. Targeted Oncology. 2022;17(1):61–68. DOI: 10.1007/s11523-021-00861-y.</mixed-citation><mixed-citation xml:lang="en">Mollica V., Santoni M., Matrana M.R., Basso U., De Giorgi U., Rizzo A. et al. Concomitant proton pump inhibitors and outcome of patients treated with nivolumab alone or plus ipilimumab for advanced renal cell carcinoma. Targeted Oncology. 2022;17(1):61–68. DOI: 10.1007/s11523-021-00861-y.</mixed-citation></citation-alternatives></ref><ref id="cit98"><label>98</label><citation-alternatives><mixed-citation xml:lang="ru">Maslov D.L., Trifonova O.P., Lichtenberg S., Balashova E.E., Mamedli Z.Z., Alferov A.A. et al. Blood plasma metabolome profiling at different stages of renal cell carcinoma. Cancers. 2022;15(1): 140. DOI: 10.3390/cancers15010140.</mixed-citation><mixed-citation xml:lang="en">Maslov D.L., Trifonova O.P., Lichtenberg S., Balashova E.E., Mamedli Z.Z., Alferov A.A. et al. Blood plasma metabolome profiling at different stages of renal cell carcinoma. Cancers. 2022;15(1): 140. DOI: 10.3390/cancers15010140.</mixed-citation></citation-alternatives></ref><ref id="cit99"><label>99</label><citation-alternatives><mixed-citation xml:lang="ru">Rankin‐Turner S., Heaney L.M. Applications of ambient ionization mass spectrometry in 2020: An annual review. Analytical Science Advances. 2021;2(3–4):193–212. DOI: 10.1002/ansa.202300004.</mixed-citation><mixed-citation xml:lang="en">Rankin‐Turner S., Heaney L.M. Applications of ambient ionization mass spectrometry in 2020: An annual review. Analytical Science Advances. 2021;2(3–4):193–212. DOI: 10.1002/ansa.202300004.</mixed-citation></citation-alternatives></ref><ref id="cit100"><label>100</label><citation-alternatives><mixed-citation xml:lang="ru">Genangeli M., Heeren R.M., Porta Siegel T. Tissue classification by rapid evaporative ionization mass spectrometry (REIMS): comparison between a diathermic knife and CO 2 laser sampling on classification performance. Analytical and Bioanalytical Chemistry. 2019;411:7943–7955. DOI: 10.1007/s00216-019-02148-8.</mixed-citation><mixed-citation xml:lang="en">Genangeli M., Heeren R.M., Porta Siegel T. Tissue classification by rapid evaporative ionization mass spectrometry (REIMS): comparison between a diathermic knife and CO 2 laser sampling on classification performance. Analytical and Bioanalytical Chemistry. 2019;411:7943–7955. DOI: 10.1007/s00216-019-02148-8.</mixed-citation></citation-alternatives></ref><ref id="cit101"><label>101</label><citation-alternatives><mixed-citation xml:lang="ru">St. John E.R., Balog J., McKenzie J.S., Rossi M., Covington A., Muirhead L. et al. Rapid evaporative ionisation mass spectrometry of electrosurgical vapours for the identification of breast pathology: towards an intelligent knife for breast cancer surgery. Breast Cancer Research. 2017;19(1):1–14. DOI: 10.1186/s13058-017-0845-2.</mixed-citation><mixed-citation xml:lang="en">St. John E.R., Balog J., McKenzie J.S., Rossi M., Covington A., Muirhead L. et al. Rapid evaporative ionisation mass spectrometry of electrosurgical vapours for the identification of breast pathology: towards an intelligent knife for breast cancer surgery. Breast Cancer Research. 2017;19(1):1–14. DOI: 10.1186/s13058-017-0845-2.</mixed-citation></citation-alternatives></ref><ref id="cit102"><label>102</label><citation-alternatives><mixed-citation xml:lang="ru">Gómez-Ríos G.A., Tascon M., Reyes-Garcés N., Boyacı E., Poole J., Pawliszyn J. Quantitative analysis of biofluid spots by coated blade spray mass spectrometry, a new approach to rapid screening. Scientific Reports. 2017;7(1):16104. DOI: 10.1038/s41598-017-16494-z.</mixed-citation><mixed-citation xml:lang="en">Gómez-Ríos G.A., Tascon M., Reyes-Garcés N., Boyacı E., Poole J., Pawliszyn J. Quantitative analysis of biofluid spots by coated blade spray mass spectrometry, a new approach to rapid screening. Scientific Reports. 2017;7(1):16104. DOI: 10.1038/s41598-017-16494-z.</mixed-citation></citation-alternatives></ref><ref id="cit103"><label>103</label><citation-alternatives><mixed-citation xml:lang="ru">St. John E.R., Rossi M., Pruski P., Darzi A., Takats Z. Intraoperative tissue identification by mass spectrometric technologies. TrAC Trends in Analytical Chemistry. 2016;85:2–9. DOI: 10.1126/scitranslmed.3005623.</mixed-citation><mixed-citation xml:lang="en">St. John E.R., Rossi M., Pruski P., Darzi A., Takats Z. Intraoperative tissue identification by mass spectrometric technologies. TrAC Trends in Analytical Chemistry. 2016;85:2–9. DOI: 10.1126/scitranslmed.3005623.</mixed-citation></citation-alternatives></ref><ref id="cit104"><label>104</label><citation-alternatives><mixed-citation xml:lang="ru">Shamraeva M.A., Bormotov D.S., Shamarina E.V., Bocharov K.V., Peregudova O.V., Pekov S.I. et al. Spherical sampler probes enhance the robustness of ambient ionization mass spectrometry for rapid drugs screening. Molecules. 2022;27(3):945. DOI: 10.3390/molecules27030945.</mixed-citation><mixed-citation xml:lang="en">Shamraeva M.A., Bormotov D.S., Shamarina E.V., Bocharov K.V., Peregudova O.V., Pekov S.I. et al. Spherical sampler probes enhance the robustness of ambient ionization mass spectrometry for rapid drugs screening. Molecules. 2022;27(3):945. DOI: 10.3390/molecules27030945.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
